Diabetic Foot Ulcer Clinical Trial
Official title:
A Multi-center, Randomized Controlled Clinical Trial Evaluating the Effect of Fresh Amniotic Membrane in the Treatment of Diabetic Foot Ulcers: Crossover Group From Standard of Care
This study is an extension of the randomized controlled trial NT-DFU-AFF-01. Subjects that were randomized to the Standard of Care group will be able to crossover to the NT-DFU-AFF-02 trial and receive Affinity fHSAM if certain criteria are met.
This study is an extension of the randomized controlled trial NT-DFU-AFF-01 in which subjects
were randomized to SOC for 12 weeks or SOC and fresh hypothermically stored human amniotic
membrane (Affinity; fHSAM) for 12 weeks to determine if addition of fHSAM to SOC results in
faster healing of Wagner grade 1 and 2 DFUs compared to SOC alone.
At 6 weeks, patients from this RCT (NT-DFU-AFF-01) with study DFUs that have not been reduced
in area by at least 40% will be exited from the study and considered treatment failures. This
group (Group 2C) will constitute the active population in this single arm study
(NT-DFU-AFF-02). Study wounds will receive up to 12 weeks of continuing SOC and fHSAM.
The standard of care therapy in this study is offloading of the DFU, appropriate sharp or
surgical debridement, and aggressive infection management with the use of appropriate
dressings (defined later in the protocol). A number of offloading systems are commercially
available. The choice of offloading will be at the discretion of the principal investigator
but should be total contact casting, fixed ankle walker boot, or equivalent device to the
fixed ankle walker boot.
The Screening Phase (1 day) consists of a series of screening assessments designed to
determine eligibility followed by, for those who meet the eligibility criteria (described in
more detail below), treatment. At the Screening Visit (S1), written informed consent from the
subject will be obtained by the Investigator or suitably qualified designee before the
performance of any other protocol-specific procedure. The Screening Period is designed to
determine whether subjects are eligible to proceed to the Treatment Phase of the study.
The Treatment Phase (12 Weeks) begins on the same day as the screening visit. During the
Treatment Phase, subjects will be evaluated on a weekly basis. Efficacy evaluations each week
will include Investigator assessment of ulcer healing and measurements of ulcer size using
digital photographic planimetry. Safety evaluations during the Treatment Phase will consist
of adverse event assessments at each visit.
Subjects whose ulcers do not achieve closure at 12 weeks or who experience an amputation will
be deemed treatment failures.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04497805 -
Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers
|
Phase 2 | |
Withdrawn |
NCT03675269 -
Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer:
|
N/A | |
Completed |
NCT04624516 -
Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence
|
N/A | |
Not yet recruiting |
NCT06439667 -
VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
|
||
Recruiting |
NCT05608187 -
Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
|
Phase 2 | |
Not yet recruiting |
NCT06278935 -
Lifestyle Tailored Offloading for Diabetic Foot Ulcers
|
N/A | |
Not yet recruiting |
NCT06437028 -
Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers.
|
N/A | |
Withdrawn |
NCT05024656 -
AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers
|
N/A | |
Terminated |
NCT02202668 -
Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers
|
N/A | |
Terminated |
NCT01966380 -
Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia
|
Phase 2 | |
Completed |
NCT01951768 -
Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection
|
Phase 4 | |
Completed |
NCT01657474 -
Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers
|
N/A | |
Active, not recruiting |
NCT00389636 -
TheraGauzeā¢ Alone and Regranex®Gel 0.01% Plus TheraGauzeā¢ in the Treatment of Wagner Stage I Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01181440 -
Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers
|
Phase 3 | |
Enrolling by invitation |
NCT05888259 -
Plantar Pressure Distribution in Diabetic Foot Ulcer
|
N/A | |
Completed |
NCT04054804 -
Digital Foot Check by Using the D-Foot, a New Software
|
||
Not yet recruiting |
NCT05877378 -
Efficacy of PICO Single-use System in Chronic Ulcers
|
N/A | |
Recruiting |
NCT06037369 -
The Short Message-based Customized Standardized
|
N/A | |
Completed |
NCT03312595 -
Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)
|
N/A | |
Recruiting |
NCT04564443 -
A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot
|
N/A |